Roth Capital re-initiates coverage on bluebird bio (NASDAQ: BLUE) with a Buy rating and a price target of $121.00.Analyst Elemer ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE